fimasartan + statin

A combination therapy of **fimasartan**, an angiotensin II receptor antagonist (ARB), and a **statin** (such as atorvastatin), a 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase inhibitor. This fixed-dose combination (FDC) is indicated for the treatment of *hypertension* and *dyslipidemia*, particularly in patients with comorbid risk factors. Fimasartan lowers blood pressure by antagonizing angiotensin II type 1 receptors, while statins lower cholesterol by inhibiting HMG-CoA reductase, the key enzyme of cholesterol biosynthesis. Both drugs can be metabolized by CYP3A4 and transported by OATP1B1/OATP1B3, with some pharmacokinetic interaction observed when coadministered: exposure to both drugs may increase, but this combination is considered well-tolerated and commonly used in clinical practice[1][3].

Other names

fimasartan + statinfimasartan + atorvastatinfimasartan/atorvastatin